The use of the investigational CDK4/6 inhibitor abemaciclib, in combination with an aromatase inhibitor or with fulvestrant, or as monotherapy, has demonstrated efficacy in patients with HER2-negative/hormone receptor–positive breast cancer in multiple settings. Read More ›

Updated National Comprehensive Cancer Network guidelines for the management of breast cancer address the use of genomic expression profiling in predicting distant recurrence as well as the benefit of adjuvant endocrine therapy and adjuvant chemotherapy. Read More ›

New guidance from the National Comprehensive Cancer Network (NCCN) defines appropriate radiation treatment targets, noting that individualizing radiation therapy based on risk is important, and that hypofractionation is now the preferred method of delivery to achieve local control and acceptable breast cosmesis. Read More ›

Three clinical trials conducted in postmenopausal women with hormone receptor (HR)-positive breast cancer showed no advantage to extending endocrine therapy beyond an initial 5 years. Read More ›

In metastatic hormone receptor (HR)-positive breast cancer, adding everolimus to fulvestrant overcomes resistance to aromatase inhibitor therapy. Read More ›

Updated guidelines for sentinel lymph node biopsy in patients with early-stage breast cancer confirm older conservative guidance. Read More ›

A sophisticated gene signature test has been shown to enhance the prediction of the clinical efficacy of chemotherapy in women with early-stage breast cancer, according to results of the recent phase 3 MINDACT study. The findings will enable many women to safely avoid chemotherapy. Read More ›

A new cyclin-dependent kinase 4/6 inhibitor has received approval as first-line therapy for advanced breast cancer based on impressive results from the randomized, phase 3 MONALEESA-2 study. Read More ›

Although 5 years of neoadjuvant endocrine therapy improves disease-free survival in patients with early-stage breast cancer, the optimal duration of adjuvant therapy beyond 5 years has yet to be established. Results of a new study, suggesting that longer is not necessarily better, provide further insight on this topic. Read More ›

An evaluation of more than 200 patients with breast cancer showed a near doubling of the risk for contralateral disease with dense breast tissue. This information may help clinicians counsel patients on their personal risk and options for treatment and surveillance. Read More ›